We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer’s radar.
Jim Cramer, host of Mad Money, shared his thoughts on factors that could lead to market growth in 2025, pointing out some key changes that could benefit investors. He expressed optimism about the shift in leadership at the Federal Trade Commission (FTC) and the Justice Department, particularly with the departure of current FTC Chief Lina Khan, whom he criticized for her harsh stance on large businesses.
“The brooming of Biden’s antitrust regulators as the FTC and the Justice Department, that will be fabulous, fabulous for the market.”
READ ALSO: Jim Cramer’s Game Plan: Top 14 Stocks to Watch and Jim Cramer Looked At These 7 Stocks Recently
According to Cramer, Khan’s approach was one of hostility toward any major business deal, regardless of the potential positive effects on the economy or on workers. He argued that with the removal of the old guard, a wave of deals could emerge that would help rationalize various industries.
This, in turn, would give smaller companies in sectors like banking, retail, entertainment, pharmaceuticals, and enterprise software a better chance to compete against larger corporations. Cramer was enthusiastic about the potential for these changes, stating, “Fantastic for the stock market. Just fantastic.”
Cramer also touched on an important issue in the market: a shortage of equities. He noted that the lack of available stock could lead to higher prices. He explained that mergers and acquisitions activity could help remove some of the available stock from the market, reducing supply and potentially driving up stock prices.
“Always remember the stock market is indeed a market and like any other market, when there’s not enough supply, you get higher prices.”
Moving on to the housing market, Cramer discussed the effects of overbuilding, like in Florida, where housing prices have been impacted. He explained that when mortgage rates rise, housing prices tend to drop. This price drop often leads to a wait-and-see approach from buyers, who hold out for even lower prices. As sellers grow more desperate, they typically lower prices further in a bid to move their properties.
“It’s called the cycle, although it hasn’t been operating normally for the last few years. I think 2025 will be the year the cycle reasserts itself and the Fed will win big on this one. Big enough to be able to cut rates slowly but cut nonetheless, which of course is what we need.”
Our Methodology
For this article, we compiled a list of 7 stocks that were discussed by Jim Cramer during an episode of Mad Money aired in January. We listed the stocks in ascending order of their hedge fund sentiment as of the third quarter, which was taken from Insider Monkey’s database of 900 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders: 106
Cramer mentioned one of the leading global pharmaceutical companies, Eli Lilly and Company (NYSE:LLY), during the Mad Money episode and said:
“Okay, the problem with Eli Lilly is people are saying, you know what, after a year, people are no longer taking the drugs, they’re going off it, a huge percentage’s going off it. I think that you own this thing because it’s about cardiac… It’s about high blood pressure. It’s about dementia, may even be about cancer, not just about weight and diabetes. So I think you hold on to Eli Lilly. We continue to hold it for the trust. I do think there’ll be good numbers, but that last quarter wasn’t good. I totally understand the trepidation about the stock, but I still like it.”
Toward the mid of January, Cramer discussed Eli Lilly’s (NYSE:LLY) stock drop, noting that the company had projected $58 to $61 billion in revenue for the coming year, driven by its GLP-1 drugs for diabetes, weight loss, and obstructive sleep apnea. However, its fourth-quarter results fell short of Wall Street’s expectations. Despite this, Cramer saw the drop as a buying opportunity, particularly due to Mounjaro’s potential in treating a wide range of conditions.
He acknowledged challenges with the drug’s launch but remains optimistic about its long-term prospects. Cramer also highlighted political factors affecting the company, including criticism of GLP-1 drugs from Robert Kennedy Jr. Despite some short-term concerns, he believes in Eli Lilly’s (NYSE:LLY) future potential and recommended buying the stock.
Overall LLY ranks 2nd on our list of the stocks on Jim Cramer’s radar. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
